Association of Bcr-Abl Tyrosine Kinase Inhibitors With Hepatitis B Virus Reactivation Requiring Antiviral Treatment in Taiwan

IMPORTANCE: The US Food and Drug Administration (FDA) highlighted the potential risk of hepatitis B reactivation that was associated with Bcr-Abl tyrosine kinase inhibitor (TKI) treatment and has required updated product labels. OBJECTIVE: To examine the association between hepatitis B flare and exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ling-Yi, Chu, Sung-Chao, Lo, Yin, Yang, Yen-Yun, Chan, K. Arnold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025118/
https://www.ncbi.nlm.nih.gov/pubmed/33822067
http://dx.doi.org/10.1001/jamanetworkopen.2021.4132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025118/
https://www.ncbi.nlm.nih.gov/pubmed/33822067
http://dx.doi.org/10.1001/jamanetworkopen.2021.4132

Ejemplares similares